Healius Limited (AU:HLS)
ASX:HLS
HLS Stock Chart & Stats
AU$0.54
-AU$0.02(-1.03%)
At close: 4:00 PM EST
AU$0.54
-AU$0.02(-1.03%)
Day’s Range― - ―
52-Week RangeAU$0.52 - AU$1.64
Previous CloseN/A
Volume575.57K
Average Volume (3M)2.94M
Market Cap
AU$388.48M
Enterprise ValueAU$1.99B
Total Cash (Recent Filing)AU$51.60M
Total Debt (Recent Filing)AU$1.66B
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 26, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding726,132,800
10 Day Avg. Volume3,249,015
30 Day Avg. Volume2,941,962
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.26
Price to Sales (P/S)0.11
P/FCF Ratio0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside38.80% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$1.40B
Bulls Say, Bears Say
Bulls Say
Diversified Diagnostic ServicesHealius’s dual focus on pathology and diagnostic imaging creates recurring, fee-for-service revenue from clinicians, hospitals and insurers. This service mix provides durable demand tied to healthcare utilization and ageing populations, supporting stable volumes and cross-sell opportunities over months to years.
Positive Operating Cash GenerationDespite accounting losses, the company generates positive operating cash flow and a relatively strong operating cash flow to net income ratio. Persistent cash generation supports day-to-day operations, liquidity management and provides runway to execute restructuring or efficiency plans over the coming quarters.
Stable Equity BaseA relatively stable equity ratio indicates the company retains a tangible capital buffer versus total assets. This stability can absorb operational shocks, facilitate access to capital markets or bank funding, and provide time to implement turnaround measures without immediate solvency pressure.
Bears Say
High LeverageA debt-to-equity ratio of 1.55 signals significant leverage that elevates refinancing and interest-rate exposure. Over a multi-month horizon, high leverage constrains strategic flexibility, increases fixed financing costs and raises the risk that earnings volatility or slower recovery could impair ability to deleverage.
Declining Revenue TrendA 13.8% revenue decline reflects material demand or referral weakness and pressures economies of scale in labs and imaging. Sustained top-line contraction can erode utilization, reduce margin leverage on fixed costs, and require structural changes to operations or pricing to restore long-term profitability.
Negative Profitability MetricsA negative net margin and negative ROE show the company is not earning returns on capital and is burning equity value. Persistent losses limit reinvestment capacity, increase reliance on external funding, and make it harder to rebuild margins without significant operational improvement or structural revenue uplift.
Healius Limited News
HLS FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest share price was AU$0.52 and its highest was AU$1.64 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is AU$388.48M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Aug 26, 2026 which is in 148 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.015 earnings per share for the quarter, missing the consensus estimate of -AU$0.001 by -AU$0.014.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Undervalued.
Does Healius Limited pay dividends?
Healius Limited pays a Notavailable dividend of AU$0.635 which represents an annual dividend yield of N/A. See more information on Healius Limited dividends here
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is 0.03.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,132,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -AU$0.015 in its last earnings report, missing expectations of -AU$0.001. Following the earnings report the stock price went down -6.748%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in AU:HLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$0.75 (38.80% Upside)
AU$0.75 (38.80% Upside)
Blogger Sentiment
Bullish
AU:HLS Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €64.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.24%
12-Months-Change
Fundamentals
Return on Equity
-67.21%
Trailing 12-Months
Asset Growth
-46.62%
Trailing 12-Months
Company Description
Healius Limited
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
HLS Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(38.80% Upside)
Technical Analysis
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---